Success Metrics

Clinical Success Rate
67.3%

Based on 33 completed trials

Completion Rate
67%(33/49)
Active Trials
5(9%)
Results Posted
115%(38 trials)
Terminated
16(28%)

Phase Distribution

Ph not_applicable
6
10%
Ph phase_3
2
3%
Ph phase_2
34
59%
Ph phase_1
16
28%

Phase Distribution

16

Early Stage

34

Mid Stage

2

Late Stage

Phase Distribution58 total trials
Phase 1Safety & dosage
16(27.6%)
Phase 2Efficacy & side effects
34(58.6%)
Phase 3Large-scale testing
2(3.4%)
N/ANon-phased studies
6(10.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.5%

33 of 52 finished

Non-Completion Rate

36.5%

19 ended early

Currently Active

5

trials recruiting

Total Trials

58

all time

Status Distribution
Active(5)
Completed(33)
Terminated(19)
Other(1)

Detailed Status

Completed33
Terminated16
Withdrawn3
Recruiting3
Active, not recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
58
Active
5
Success Rate
67.3%
Most Advanced
Phase 3

Trials by Phase

Phase 116 (27.6%)
Phase 234 (58.6%)
Phase 32 (3.4%)
N/A6 (10.3%)

Trials by Status

active_not_recruiting23%
withdrawn35%
unknown12%
terminated1628%
completed3357%
recruiting35%

Recent Activity

Clinical Trials (58)

Showing 20 of 58 trialsScroll for more
NCT03164057Phase 2

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active Not Recruiting
NCT06207799Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting
NCT01511562Phase 2

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Active Not Recruiting
NCT05787574Phase 2

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Recruiting
NCT02512497Phase 1

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Completed
NCT01666080Not Applicable

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

Recruiting
NCT02162420Not Applicable

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Completed
NCT00179842Phase 2

Immune Ablation and Stem Cell Support for Crohn's Disease

Withdrawn
NCT00936936Phase 2

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Completed
NCT00968760Phase 1

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Completed
NCT00167219Phase 1

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

Completed
NCT01746173Phase 2

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Terminated
NCT00177047Phase 2

Autologous Transplant for Multiple Myeloma

Completed
NCT00813124Phase 2

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Completed
NCT00591630Phase 2

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Completed
NCT00943800Not Applicable

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Completed
NCT00176930Not Applicable

Stem Cell Transplant for Hematological Malignancy

Terminated
NCT00741455Not Applicable

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Completed
NCT02750254Phase 1

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Terminated
NCT00506948Phase 2

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Terminated

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
58